Chemo intranipple injection may help target milk ducts to treat breast cancer; FDA accepts BioDelivery's Bunavail NDA for opioid dependence;

> Boston researchers are looking to target milk ducts to fight breast cancer with an intranipple injection of chemotherapy, delivering drugs directly to the root of many forms of the disease. Story

> The FDA accepted an NDA from BioDelivery Sciences ($BDSI) for the company's Bunavail opioid-dependence treatment, which uses BioDelivery's BioErodible MucoAdhesive delivery technology to treat cancer pain. More

> Dicerna Pharmaceuticals presented proof-of-concept data to support the slicing of oncogenes in the company's approach to RNAi treatments. Release

> 3M Drug Delivery Systems will manufacture ProStrakan Group's Sancuso transdermal patch in Europe with recent EMA approval. Worn under the arm, Sancuso controls chemotherapy-induced nausea and vomiting. More

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.